🔍

Jubilant Ingrevia Limited (JUBLINGREA)

📊 NSE: JUBLINGREA 🏢 Chemicals 📅 Last Updated: 12/14/2025 8:43

📢 Recent Corporate Announcements

Jubilant Ingrevia AGM Approves Rs 2.50/Share Final Dividend; All 5 Resolutions Passed

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 26 Aug 2026, 09:52 PM

Jubilant Ingrevia Limited held its 7th Annual General Meeting (AGM) on August 26, 2026, where shareholders approved all five resolutions with requisite majorities. Key approvals included the adoption of FY26 financial statements and the declaration of a final dividend of Rs 2.50 per equity share of Re 1 face value. Re-appointments of directors Mr. Shyam S. Bhartia and Mr. Priyavrat Bhartia received 95.61% and 93.15% voting approval, respectively. Overall voting turnout reached 72.90%, representing 11.61 crore polled votes.

Approved final dividend of Rs 2.50 per equity share (face value Re 1) with 99.997% assent
Total voting turnout stood at 72.90% (11.61 crore votes polled out of 15.93 crore outstanding shares)
Re-appointment of Mr. Shyam S. Bhartia and Mr. Priyavrat Bhartia approved with 95.61% and 93.15% assent
Adoption of FY26 standalone and consolidated financial statements approved by 99.997% of votes

💡 Track the dividend disbursement schedule following AGM approval and watch for ongoing operational updates regarding the multi-purpose plant expansion at Gajraula.

Jubilant Ingrevia Shareholders Approve Rs 2.50/Share Final Dividend at 7th AGM

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 26 Aug 2026, 09:50 PM

Jubilant Ingrevia Limited announced that all 5 ordinary resolutions at its 7th Annual General Meeting held on August 26, 2026, were passed with requisite majorities. Key resolutions approved include the adoption of FY26 audited financial statements and a final dividend of Rs 2.50 per equity share (99.997% approval). Shareholders also approved the re-appointment of directors Mr. Shyam S. Bhartia (95.61% assent) and Mr. Priyavrat Bhartia (93.15% assent) along with cost auditor remuneration.

Final dividend of Rs 2.50 per equity share of Re 1 approved with 99.997% shareholder assent
Adoption of FY26 standalone and consolidated financial statements approved with 99.997% votes in favour
Re-appointment of Mr. Shyam S. Bhartia approved with 95.612% assent; Mr. Priyavrat Bhartia re-appointment passed with 93.149% assent
A total of 82 shareholders attended the virtual AGM representing 1,13,065 total shareholder base

💡 Track the dividend payout timeline and watch for progress on the Pinnacle 345 growth roadmap and Gajraula MPP commissioning in upcoming quarterly updates.

₹189.2 Cr Stake Buy: Jubilant Ingrevia to Acquire 40% in Zettaone Technologies

🟢 POSITIVE ⭐ 7/10

M&A 📅 18 Aug 2026, 09:37 PM

Jubilant Ingrevia has entered into a binding term sheet to acquire a 40% strategic equity stake in Zettaone Technologies India Pvt. Ltd. for approximately ₹189.2 crore in cash. Zettaone is an electronics design and manufacturing platform (EDMS) with FY26 turnover of ₹98.1 crore (growing from ₹51.1 crore in FY24). The transaction will be completed in two tranches—tranche 1 by November 2026 and tranche 2 by September 2027—making Zettaone an associate company. This investment aligns with Jubilant Ingrevia's 'Pinnacle' strategy to build an integrated value chain across electronics and semiconductor spaces.

Acquisition of 40% strategic equity stake in Zettaone Technologies for ₹189.2 crore in cash
Target entity generated FY26 turnover of ₹98.1 crore, up from ₹79.1 crore in FY25 and ₹51.1 crore in FY24
Two-tranche completion schedule: Tranche 1 by November 2026 and Tranche 2 by September 2027
Transaction represents ~7.2% of Jubilant Ingrevia's net worth (₹2,640 crore) and ~1.6% of its market cap

💡 Track the closure of Tranche 1 by November 2026 and monitor synergy disclosures regarding CDMO cross-selling into semiconductor and electronics sectors in upcoming earnings calls.

Jubilant Ingrevia to Acquire 40% Stake in Zettaone for ₹189.2 Cr

🟢 POSITIVE ⭐ 7/10

M&A 📅 18 Aug 2026, 07:43 PM

Jubilant Ingrevia has entered into a binding term sheet to acquire a 40% strategic equity stake in Zettaone Technologies India Private Limited for approximately ₹189.2 crore in cash. The acquisition will be completed in two tranches, with the first closing expected by November 2026 and the second by September 2027, making Zettaone an associate company. Zettaone operates in electronics design and manufacturing (EDMS), posting revenue of ₹98.1 crore in FY26, up from ₹79.1 crore in FY25 and ₹51.1 crore in FY24. This transaction advances Jubilant's 'Pinnacle' strategy into the semiconductor and electronics value chain.

Acquiring a 40% strategic equity stake in Zettaone Technologies for an aggregate cash consideration of ₹189.2 crore.
Target company revenue grew 92% over two years, from ₹51.1 crore in FY24 to ₹79.1 crore in FY25 and ₹98.1 crore in FY26.
Two-tranche closing schedule: Tranche 1 by November 2026 and Tranche 2 by September 2027.
Deal value of ₹189.2 crore represents ~7.2% of Jubilant Ingrevia's net worth (₹2,640 crore) and ~4.1% of TTM revenue (₹4,651 crore).

💡 Monitor the definitive agreement signing and closing of Tranche 1 by November 2026, alongside management commentary on synergistic customer cross-selling between CDMO chemicals and EDMS.

Jubilant Ingrevia to Attend Nuvama India Conference in Singapore on August 11-12, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 04 Aug 2026, 05:55 PM

Jubilant Ingrevia Limited has scheduled participation in the Nuvama India Conference 2026, to be held in Singapore on August 11th and 12th, 2026. The management will engage in one-on-one meetings with institutional investors and analysts. These discussions will be based on publicly available information and are part of the company's routine investor relations activities. The company currently maintains a market capitalization of ₹11,911 Cr and reported a TTM revenue of ₹4,389 Cr.

Management to participate in the Nuvama India Conference 2026 on August 11-12, 2026
Meetings will be conducted in-person in Singapore as one-on-one sessions
Company reported TTM revenue of ₹4,389 Cr and TTM PAT of ₹277 Cr
Current market capitalization stands at ₹11,911 Cr with a P/E of 43.0

💡 Investors should monitor for any investor presentations uploaded to the exchange following the conference for updates on the 'Pinnacle 345' strategy and the $300M+ CDMO contract progress.

Jubilant Ingrevia to Attend Nuvama India Conference in Singapore on Aug 11-12, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 04 Aug 2026, 05:54 PM

Jubilant Ingrevia has scheduled participation in the Nuvama India Conference 2026, to be held in Singapore on August 11th and 12th, 2026. The management will engage in one-on-one, in-person meetings with institutional investors and analysts. These discussions will be restricted to generally available public information. This interaction comes as the company pursues its 'Pinnacle 345' strategy to significantly scale revenue and EBITDA over five years.

Management to participate in the Nuvama India Conference 2026 on August 11-12, 2026
Meetings will be held in-person in Singapore as one-on-one sessions
Company currently maintains a TTM revenue of ₹4,389 Cr and a market cap of ₹11,911 Cr
Discussions will focus on publicly available information only

💡 Investors should watch for any updated investor presentations filed on the exchanges following the conference for potential updates on the USD 300M+ CDMO contract execution.

Jubilant Ingrevia FY26 BRSR: Exports at 44.3% of Rs 4,388 Cr Revenue; 6th Plant Added

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 01 Aug 2026, 06:28 PM

Jubilant Ingrevia has released its Business Responsibility and Sustainability Report (BRSR) for FY 2025-26, reporting a consolidated turnover of Rs 4,388.06 crore. The company maintains a strong global footprint with exports contributing 44.32% of total revenue across 62 countries. Operationally, the company expanded its manufacturing base by acquiring a new plant on March 30, 2026, bringing its total Indian plant count to six. Specialty Chemicals remains the dominant segment, accounting for 44.13% of the total turnover.

Consolidated turnover for FY 2025-26 reached Rs 4,388.06 crore.
Exports contributed 44.32% to the total turnover, serving 62 international countries.
Specialty Chemicals segment is the largest business activity, contributing 44.13% of turnover.
Acquired 1 new plant on March 30, 2026 (Remidex Pharma), totaling 6 manufacturing plants in India.
Permanent employee turnover rate increased to 19.6% in FY26 from 18.2% in FY25.

💡 Monitor the integration of the newly acquired Remidex Pharma plant and the execution of the $300M+ CDMO contract starting in 2026 as part of the 'Pinnacle 345' strategy.

Jubilant Ingrevia Reports 44.3% Export Share in FY26 BRSR; Final Dividend TDS Update

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 01 Aug 2026, 06:22 PM

Jubilant Ingrevia has submitted its Business Responsibility and Sustainability Report (BRSR) for FY 2025-26, detailing a revenue mix where Specialty Chemicals lead at 44.13%. The company maintained a strong global presence with exports contributing 44.32% of total turnover across 62 countries. A key operational update includes the acquisition of a new plant on March 30, 2026, bringing the total national manufacturing locations to six. Additionally, the company issued a communication to shareholders regarding Tax Deducted at Source (TDS) for the FY 2025-26 final dividend.

Specialty Chemicals segment contributed 44.13% of the total turnover in FY 2025-26
Exports accounted for 44.32% of consolidated turnover, serving 62 international countries
Acquired 1 new plant on March 30, 2026, bringing the total to 6 manufacturing facilities in India
Permanent employee turnover rate increased to 19.6% in FY 2026 from 18.2% in FY 2025
Workforce includes 1,244 contract workers, representing 84% of the total worker base

💡 Investors should monitor the operational integration of the newly acquired plant and the execution of the 'Pinnacle 345' revenue-tripling strategy in upcoming quarterly earnings.

Jubilant Ingrevia FY26 BRSR: 44.32% Revenue from Exports; 6th Plant Added via Acquisition

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 01 Aug 2026, 06:16 PM

Jubilant Ingrevia Limited has released its Business Responsibility and Sustainability Report (BRSR) for FY 2025-26, reporting a consolidated turnover of ₹4,388.07 crore. The company maintains a strong global footprint, serving 62 countries with exports contributing 44.32% of total revenue. The Specialty Chemicals segment remains the primary driver, accounting for 44.13% of turnover. Operationally, the company expanded to 6 manufacturing plants following the acquisition of Remidex Pharma Private Limited on March 30, 2026.

Exports contributed 44.32% to the total turnover in FY 2025-26, serving 62 international markets.
Specialty Chemicals segment led revenue contribution at 44.13%, followed by Chemical Intermediates at 37.87%.
Manufacturing footprint increased to 6 plants in India, including the acquisition of Remidex Pharma on March 30, 2026.
Permanent employee turnover rate was reported at 19.6% for FY 2026, up from 18.2% in FY 2025.
The company maintains a workforce of 1,951 permanent employees and 1,478 workers, with 84% of workers being contract-based.

💡 Investors should monitor the integration of the newly acquired Remidex Pharma and the execution of the 'Pinnacle 345' strategy aimed at tripling revenue over five years.

₹2.50 Final Dividend Proposed in Jubilant Ingrevia's 7th AGM Notice

🟡 NEUTRAL ⭐ 4/10

ROUTINE 📅 01 Aug 2026, 05:44 PM

Jubilant Ingrevia has issued a notice for its 7th Annual General Meeting (AGM) to be held on August 26, 2026. The primary agenda includes the declaration of a final dividend of ₹2.50 per equity share for FY26, totaling an estimated payout of ~₹39.6 Cr. This represents a payout ratio of approximately 14.3% of the FY26 PAT (₹277.1 Cr). Other items include the re-appointment of promoter directors Shyam S. Bhartia and Priyavrat Bhartia, and the ratification of cost auditor fees.

Final dividend of ₹2.50 per equity share (250% of face value) proposed for FY26.
AGM scheduled for August 26, 2026, at 3:00 PM IST via Video Conferencing.
Cut-off date for e-voting eligibility set for Wednesday, August 19, 2026.
Ratification of Cost Auditor remuneration at ₹4,75,000 plus taxes for FY27.
Re-appointment of promoter directors Shyam S. Bhartia and Priyavrat Bhartia who retire by rotation.

💡 Investors should note the cut-off date of August 19, 2026, for voting eligibility and monitor the announcement of the official record date for the dividend payment.

Jubilant Ingrevia Q1 FY27: Rs 1,300 Cr Revenue Hits 15-Quarter High; EBITDA Up 36% YoY

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 27 Jul 2026, 08:10 PM

Jubilant Ingrevia reported a strong start to FY27 with revenue growing 25% YoY to Rs 1,300 crore, a 15-quarter high. EBITDA increased 36% YoY to Rs 209 crore, driven by a massive 240% surge in the Chemical Intermediates segment and steady 26% margins in Specialty Chemicals. The company confirmed its 'Pinnacle 345' growth strategy, supported by a $300M+ 5-year CDMO contract with take-or-pay protection and a pipeline of 100+ molecules with Rs 3,500+ crore peak revenue potential. Management expects sequential improvements throughout the year as new capacities like the Gajraula MPP commission by late 2026.

Revenue reached Rs 1,300 crore, representing 25% YoY growth and a 15-quarter high.
Chemical Intermediates EBITDA surged 240% YoY to Rs 57 crore due to robust demand and price escalations.
CDMO pipeline expanded to 100+ molecules with a peak revenue potential of Rs 3,500+ crore.
Confirmed $300M+ 5-year CDMO contract includes full take-or-pay protection for the company.
New Multi-Purpose Plant (MPP) at Gajraula remains on track for commissioning by the end of calendar year 2026.

💡 Monitor the execution timeline of the Gajraula MPP and the Bharuch CDMO Agro plant, as these are critical to fulfilling the $300M+ contract and achieving the 'Pinnacle 345' revenue targets.

Jubilant Ingrevia Submits Newspaper Publication of Q1 FY27 Financial Results

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 24 Jul 2026, 01:36 PM

Jubilant Ingrevia Limited has submitted copies of newspaper advertisements for its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The results were approved by the Board of Directors on July 22, 2026, and published in Financial Express, Jansatta, and Hindustan on July 24, 2026. This is a standard regulatory filing following the quarterly earnings announcement. The company also included a notice regarding the transfer of shares to the Investor Education and Protection Fund (IEPF) for unclaimed dividends since FY 2018-19.

Board of Directors approved the Q1 FY27 results on July 22, 2026
Newspaper advertisements published on July 24, 2026, in English and Hindi dailies
Notice issued for transfer of shares to IEPF for dividends unclaimed for 7 consecutive years since FY 2018-19
Quarterly results cover the period ending June 30, 2026

💡 Investors should focus on the actual Q1 FY27 earnings performance (approved July 22) rather than this procedural filing to assess progress on the 'Pinnacle 345' growth plan.

Jubilant Ingrevia Releases Q1 FY27 Earnings Call Recording

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 23 Jul 2026, 09:15 PM

Jubilant Ingrevia has published the audio recording of its investor conference call held on July 23, 2026, following the release of its Q1 FY27 financial results. The company, which reported a TTM revenue of ₹4,389 Cr and an OPM of 12.9%, is currently executing its 'Pinnacle 345' strategy to triple revenue over five years. This call likely covers progress on the ₹2,500 Cr+ (USD 300M+) CDMO contract and the commissioning of new facilities in Bharuch and Gajraula.

Conference call held on July 23, 2026, for the quarter ending June 30, 2026
Company is pursuing a 'Pinnacle 345' plan to triple revenue and quadruple EBITDA in 5 years
A major USD 300M+ (approx. ₹2,500 Cr) CDMO contract is slated to begin in early 2026
Targeting ₹100 Cr+ in annualized cost savings through 'Lean 2.0' efficiency program in FY26

💡 Investors should listen to the recording for management commentary on the execution timeline of the Gajraula Multi-Purpose Plant (MPP) and the ramp-up of the Bharuch CDMO facility.

41% PAT Growth: Jubilant Ingrevia Reports 15-Quarter High Revenue of ₹1,300 Cr in Q1 FY27

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 22 Jul 2026, 02:34 PM

Jubilant Ingrevia delivered a strong Q1 FY27 with revenue growing 25% YoY to ₹1,300 crore, driven by robust demand in Chemical Intermediates and Nutrition segments. PAT surged 41% YoY to ₹106 crore, while EBITDA margins expanded to 16% from 15% in the previous year. The company reported a significant recovery in Chemical Intermediates EBITDA, which grew 240% YoY to ₹57 crore. Management highlighted a robust CDMO/Fine Chemicals pipeline of 100+ molecules with a peak revenue potential exceeding ₹3,500 crore.

Revenue reached a 15-quarter high of ₹1,300 crore, up 25% YoY and 10% QoQ.
PAT increased 41% YoY to ₹106 crore, with EPS rising to ₹6.7 from ₹4.7 in Q1 FY26.
Chemical Intermediates segment revenue grew 38% YoY to ₹524 crore with EBITDA margins jumping from 4% to 11%.
CDMO/Fine Chemicals pipeline stands at 100+ molecules with ₹3,500+ crore peak revenue potential.
Targeting ₹100 crore in annualized lean cost savings for FY27.

💡 Watch for the commissioning of the new Multi-Purpose Plant (MPP) by late 2026 and the ramp-up of the USD 300M+ CDMO contract which is critical for the 'Pinnacle 345' growth strategy.

41% PAT Growth: Jubilant Ingrevia Reports Strong Q1 FY27 with ₹1,300 Cr Revenue

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 22 Jul 2026, 02:33 PM

Jubilant Ingrevia reported a strong start to FY27 with revenue growing 25% YoY to ₹1,300 crore, marking a 15-quarter high. Net profit surged 41% YoY to ₹106 crore, driven by a significant rebound in the Chemical Intermediates segment where EBITDA grew 240% YoY. EBITDA margins improved to 16% from 15% a year ago, supported by cost pass-through and a richer product mix in CDMO and Fine Chemicals. The company maintains a robust CDMO pipeline of 100+ molecules with a peak revenue potential of ₹3,500+ crore.

Revenue reached a 15-quarter high of ₹1,300 crore, representing 25% YoY and 10% QoQ growth.
PAT increased by 41% YoY to ₹106 crore, with EPS rising to ₹6.7 from ₹4.7 in Q1 FY26.
Chemical Intermediates EBITDA surged 240% YoY to ₹57 crore due to robust demand and price escalations.
CDMO pipeline includes 100+ molecules with a peak revenue potential exceeding ₹3,500 crore.
Nutrition segment EBITDA reached a 3-year high of ₹36 crore, up 45% YoY with 15% margins.

💡 Monitor the commissioning of the new Multi-Purpose Plant (MPP) scheduled for late 2026 and the ramp-up of the USD 300M+ CDMO contract which is critical for the 'Pinnacle 345' strategy.

View All JUBLINGREA Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Specialty Chemicals (SC) grew 15% YoY in FY25 to INR 1,818 Cr and 12% YoY in Q2 FY26. Nutrition & Health Solutions (NHS) reported INR 181 Cr in Q2 FY26, a 1% QoQ increase but 1% YoY decline. Chemical Intermediates (CI) achieved its highest quarterly revenue in 6 quarters in Q2 FY26 despite pricing pressures.

Geographic Revenue Split

Domestic India accounts for 53% of revenue. International markets contribute 47%, with Europe and Japan at 29%, and China/Rest of World at 18%. US revenue grew significantly by 52% YoY in FY25.

Profitability Margins

Standalone Profit After Tax (PAT) was INR 251.2 Cr in FY25, up 37% YoY with a 6.0% margin. Q2 FY26 PAT grew 18% YoY to INR 70 Cr. Operating margins are expected to sustain at 13-15% over the medium term as the product mix shifts toward higher-margin SC and NHS segments.

EBITDA Margin

Consolidated EBITDA margin improved to 12.4% in FY25 from 10.2% in FY24. Specialty Chemicals achieved a record 27% margin in Q4 FY25 and maintained 26% in Q2 FY26. Overall EBITDA grew 8% YoY in Q2 FY26 and 18% in H1 FY26.

Capital Expenditure

The company incurred INR 1,800 Cr in capex between FY22 and FY25. Planned capex for FY26 is approximately INR 600 Cr, primarily for the CDMO Agro plant at Bharuch and a new multipurpose facility at Gajraula.

Credit Rating & Borrowing

Crisil reaffirmed 'Crisil A1+' for commercial paper. India Ratings affirmed 'IND AA+/Stable/IND A1+' for bank loan facilities of INR 2,388.38 Cr. Interest coverage ratio improved to ~10 times in FY25 from 8.67 times in FY24.

⚙️ Operational Drivers

Raw Materials

Key raw materials include Acetic Acid (for Acetyls/CI segment), Pyridine, and Picolines. The company is significantly backwards integrated in Pyridine and Picolines, which supports its cost leadership in Specialty Chemicals.

Import Sources

China is mentioned as a historical source and a competitor region; the company has de-risked its Pyridine exposure to China by entering other geographies like Europe and Japan.

Capacity Expansion

Groundbreaking of a new Multi-Purpose Plant (MPP) in Gajraula is underway with completion expected by late 2026. A new CDMO Agro plant is also being commissioned at Bharuch to serve a major USD 300M+ contract.

Raw Material Costs

Raw material costs are impacted by global pricing volatility; however, vertical integration in Pyridine and Acetyls helps mitigate these fluctuations. Lean 1.0 initiatives delivered INR 120 Cr in annualised savings.

Manufacturing Efficiency

Lean 2.0 has been launched to deliver an additional INR 100 Cr+ in annualised cost savings in FY26. The company focuses on digitising operations to maintain cost leadership.

📈 Strategic Growth

Expected Growth Rate

25%

Growth Strategy

The 'Pinnacle 345' plan aims to triple revenue and quadruple EBITDA in 5 years. This will be achieved through a USD 300M+ 5-year CDMO contract starting in early 2026, entry into high-tech semiconductor chemicals with a new R&D facility in Greater Noida, and expanding Diketene derivative capacities.

Products & Services

Pyridine, Picolines, Diketene derivatives, Acetic Anhydride, Ethyl Acetate, Vitamin B3 (Niacinamide), Choline Chloride, and CDMO services for agrochemical and pharmaceutical innovators.

New Products/Services

New product launches include high-purity semiconductor chemicals and expanded human nutrition solutions. The CDMO segment has a funnel of 100+ new opportunities.

Market Expansion

Targeting increased export share (currently 47%) and deeper penetration in the US market, which saw 52% growth in FY25. Entry into the semiconductor innovation space via the Greater Noida R&D facility.

Market Share & Ranking

Global leadership in pyridine derivatives and a leading market position across most core products.

Strategic Alliances

Signed a USD 300+ million, five-year CDMO contract with a leading multinational agrochemical innovator.

🌍 External Factors

Industry Trends

The industry is seeing a steady recovery in volumes but pricing remains under pressure. There is a shift toward sustainable 'green' chemical variants and increased outsourcing to CDMOs (market projected to reach USD 319.6 billion by 2029).

Competitive Landscape

Competes with global players and Chinese manufacturers. European competitors are currently disadvantaged by elevated energy costs and weaker demand.

Competitive Moat

Moat is built on deep vertical integration (Pyridine/Acetyls), cost leadership through Lean initiatives, and high switching costs in the CDMO segment due to regulatory and technical complexity.